Technical Analysis for REDIF - Redhill Biopharma Ltd

Grade Last Price % Change Price Change
grade D 0.67 -4.29% -0.0300
REDIF closed down 4.29 percent on Thursday, December 5, 2019, on 5.74 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical REDIF trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Volume Surge Other -4.29%
Narrow Range Bar Range Contraction -4.29%
Gapped Down Weakness -4.29%
Narrow Range Bar Range Contraction -6.94%
Gapped Up Strength -6.94%
New 52 Week Closing Low Bearish 3.08%
Older signals for REDIF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Medicine Medical Specialties RTT Cancer Biopharmaceutical Clinical Medicine Crohn's Disease Diarrhea Irritable Bowel Syndrome Cholangiocarcinoma Gastrointestinal Diseases Gastrointestinal Tract Gastritis Inflammatory Gastrointestinal Products

Is REDIF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.97
52 Week Low 0.65
Average Volume 5,227
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.7365
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.0079
MACD Signal Line -0.0016
MACD Histogram -0.0063
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.6700
Resistance 3 (R3) 0.6700 0.6700 0.6700
Resistance 2 (R2) 0.6700 0.6700 0.6700 0.6700
Resistance 1 (R1) 0.6700 0.6700 0.6700 0.6700 0.6700
Pivot Point 0.6700 0.6700 0.6700 0.6700 0.6700
Support 1 (S1) 0.6700 0.6700 0.6700 0.6700 0.6700
Support 2 (S2) 0.6700 0.6700 0.6700 0.6700
Support 3 (S3) 0.6700 0.6700 0.6700
Support 4 (S4) 0.6700